Patients with Duchenne muscular dystrophy (DMD) are prescribed corticosteroid anti-inflammatory drugs as standard of care, but long-term use comes with significant adverse effects. For individuals ...

BOULDER, Colo., March 10, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 MDA Clinical and Scientific ...

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (CAPR) (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of ...

Dyne Therapeutics reports positive long-term data for DYNE-251 in Duchenne muscular dystrophy, aiming for U.S. accelerated approval in 2026. Dyne Therapeutics announced new long-term clinical data ...

SAN FRANCISCO -- Givinostat (Duvyzat) had a manageable long-term safety profile in Duchenne muscular dystrophy, data from an open-label extension study suggested. Most treatment-emergent adverse ...

RegenXBio Inc. ((RGNX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

Duchenne muscular dystrophy (DMD) is a genetic condition that causes increasing muscle weakness over time. While DMD currently has no cure, researchers are studying potential new treatments. When ...

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...

Please see Important Safety Information below and the full Prescribing Information. CONCORD, Mass., Aug. 25, 2025 /PRNewswire/ -- ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today ...

Your muscles need continuous maintenance to stay strong and healthy. Duchenne muscular dystrophy (DMD) happens when there is a change in a person's genetic instructions that affects the production of ...